Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 8 August 1997:
Vol. 277. no. 5327, pp. 815 - 818
DOI: 10.1126/science.277.5327.815
Prev | Table of Contents | Next

Reports

An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL

Guohua Pan, * Jian Ni, * Ying-Fei Wei, * Guo-liang Yu, Reiner Gentz, Vishva M. Dixit dagger

TRAIL, also called Apo2L, is a cytotoxic protein that induces apoptosis of many transformed cell lines but not of normal tissues, even though its death domain-containing receptor, DR4, is expressed on both cell types. An antagonist decoy receptor (designated as TRID for TRAIL receptor without an intracellular domain) that may explain the resistant phenotype of normal tissues was identified. TRID is a distinct gene product with an extracellular TRAIL-binding domain and a transmembrane domain but no intracellular signaling domain. TRID transcripts were detected in many normal human tissues but not in most cancer cell lines examined. Ectopic expression of TRID protected mammalian cells from TRAIL-induced apoptosis, which is consistent with a protective role. Another death domain-containing receptor for TRAIL (designated as death receptor-5), which preferentially engaged a FLICE (caspase-8)-related death protease, was also identified.

G. Pan and V. M. Dixit, Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
J. Ni, Y.-F. Wei, G.-L. Yu, R. Gentz, Human Genome Sciences, 9410 Key West Avenue, Rockville, MD 20850-3338, USA.
*   These authors share first authorship.

dagger    To whom correspondence should be addressed at Genentech, Inc., 1 DNA Way, M/S-40, So. San Francisco, CA 94080, USA. E-mail: dixit{at}gene.com

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Factor VIII-von Willebrand Factor Complex Inhibits Osteoclastogenesis and Controls Cell Survival.
M. Baud'huin, L. Duplomb, S. Teletchea, C. Charrier, M. Maillasson, M. Fouassier, and D. Heymann (2009)
J. Biol. Chem. 284, 31704-31713
   Abstract »    Full Text »    PDF »
Mapatumumab, an Antibody Targeting TRAIL-R1, in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Malignancies: Results of a Phase I and Pharmacokinetic Study.
S. Leong, R. B. Cohen, D. L. Gustafson, C. J. Langer, D. R. Camidge, K. Padavic, L. Gore, M. Smith, L. Q. Chow, M. von Mehren, et al. (2009)
J. Clin. Oncol. 27, 4413-4421
   Abstract »    Full Text »    PDF »
Life and death by death receptors.
M. E. Guicciardi and G. J. Gores (2009)
FASEB J 23, 1625-1637
   Abstract »    Full Text »    PDF »
Enhancement of Lexatumumab-Induced Apoptosis in Human Solid Cancer Cells by Cisplatin in Caspase-Dependent Manner.
X.-X. Wu and Y. Kakehi (2009)
Clin. Cancer Res. 15, 2039-2047
   Abstract »    Full Text »    PDF »
LY303511 Enhances TRAIL Sensitivity of SHEP-1 Neuroblastoma Cells via Hydrogen Peroxide-Mediated Mitogen-Activated Protein Kinase Activation and Up-regulation of Death Receptors.
K. Shenoy, Y. Wu, and S. Pervaiz (2009)
Cancer Res. 69, 1941-1950
   Abstract »    Full Text »    PDF »
Melittin, a Major Component of Bee Venom, Sensitizes Human Hepatocellular Carcinoma Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Activating CaMKII-TAK1-JNK/p38 and Inhibiting I{kappa}B{alpha} Kinase-NF{kappa}B.
C. Wang, T. Chen, N. Zhang, M. Yang, B. Li, X. Lu, X. Cao, and C. Ling (2009)
J. Biol. Chem. 284, 3804-3813
   Abstract »    Full Text »    PDF »
Anti-Gout Agent Allopurinol Exerts Cytotoxicity to Human Hormone-Refractory Prostate Cancer Cells in Combination with Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand.
T. Yasuda, T. Yoshida, A. E. Goda, M. Horinaka, K. Yano, T. Shiraishi, M. Wakada, Y. Mizutani, T. Miki, and T. Sakai (2008)
Mol. Cancer Res. 6, 1852-1860
   Abstract »    Full Text »    PDF »
TRAIL Resistance of Breast Cancer Cells Is Associated with Constitutive Endocytosis of Death Receptors 4 and 5.
Y. Zhang and B. Zhang (2008)
Mol. Cancer Res. 6, 1861-1871
   Abstract »    Full Text »    PDF »
Cooperation of the Agonistic DR5 Antibody Apomab with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival.
H. Jin, R. Yang, J. Ross, S. Fong, R. Carano, K. Totpal, D. Lawrence, Z. Zheng, H. Koeppen, H. Stern, et al. (2008)
Clin. Cancer Res. 14, 7733-7740
   Abstract »    Full Text »    PDF »
Baicalein Overcomes Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance via Two Different Cell-Specific Pathways in Cancer Cells but not in Normal Cells.
H. Taniguchi, T. Yoshida, M. Horinaka, T. Yasuda, A. E. Goda, M. Konishi, M. Wakada, K. Kataoka, T. Yoshikawa, and T. Sakai (2008)
Cancer Res. 68, 8918-8927
   Abstract »    Full Text »    PDF »
Early Therapy Evaluation of Combined Anti-Death Receptor 5 Antibody and Gemcitabine in Orthotopic Pancreatic Tumor Xenografts by Diffusion-Weighted Magnetic Resonance Imaging.
H. Kim, D. E. Morgan, D. J. Buchsbaum, H. Zeng, W. E. Grizzle, J. M. Warram, C. R. Stockard, L. R. McNally, J. W. Long, J. C. Sellers, et al. (2008)
Cancer Res. 68, 8369-8376
   Abstract »    Full Text »    PDF »
ABT-737 Induces Expression of the Death Receptor 5 and Sensitizes Human Cancer Cells to TRAIL-induced Apoptosis.
J. H. Song, K. Kandasamy, and A. S. Kraft (2008)
J. Biol. Chem. 283, 25003-25013
   Abstract »    Full Text »    PDF »
Breast Tumor Xenografts: Diffusion-weighted MR Imaging to Assess Early Therapy with Novel Apoptosis-Inducing Anti-DR5 Antibody.
H. Kim, D. E. Morgan, H. Zeng, W. E. Grizzle, J. M. Warram, C. R. Stockard, D. Wang, and K. R. Zinn (2008)
Radiology 248, 844-851
   Abstract »    Full Text »    PDF »
Hypoxia-inducible factor-2{alpha} regulates the expression of TRAIL receptor DR5 in renal cancer cells.
S. Mahajan, V. Dammai, T. Hsu, and A.S. Kraft (2008)
Carcinogenesis 29, 1734-1741
   Abstract »    Full Text »    PDF »
Sp1-Mediated TRAIL Induction in Chemosensitization.
J. Xu, J.-Y. Zhou, W.-Z. Wei, S. Philipsen, and G. S. Wu (2008)
Cancer Res. 68, 6718-6726
   Abstract »    Full Text »    PDF »
Cloning and apoptosis-inducing activities of canine and feline TRAIL.
S. Rong, J. H. Cai, and J. Andrews (2008)
Mol. Cancer Ther. 7, 2181-2191
   Abstract »    Full Text »    PDF »
TRAIL Inactivates the Mitotic Checkpoint and Potentiates Death Induced by Microtubule-Targeting Agents in Human Cancer Cells.
M. Kim, J. Liao, M. L. Dowling, K. R. Voong, S. E. Parker, S. Wang, W. S. El-Deiry, and G. D. Kao (2008)
Cancer Res. 68, 3440-3449
   Abstract »    Full Text »    PDF »
Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature.
L. Cao, P. Du, S.-H. Jiang, G.-H. Jin, Q.-L. Huang, and Z.-C. Hua (2008)
Mol. Cancer Ther. 7, 851-861
   Abstract »    Full Text »    PDF »
TRAIL Stimulates Proliferation of Vascular Smooth Muscle Cells via Activation of NF-{kappa}B and Induction of Insulin-like Growth Factor-1 Receptor.
M. M. Kavurma, M. Schoppet, Y. V. Bobryshev, L. M. Khachigian, and M. R. Bennett (2008)
J. Biol. Chem. 283, 7754-7762
   Abstract »    Full Text »    PDF »
The Puzzling Role of TRAIL in Endothelial Cell Biology.
P. Secchiero and G. Zauli (2008)
Arterioscler Thromb Vasc Biol 28, e4
   Full Text »    PDF »
DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines.
L. M. Laguinge, R. N. Samara, W. Wang, W. S. El-Deiry, G. Corner, L. Augenlicht, L. Mishra, and J. M. Jessup (2008)
Cancer Res. 68, 909-917
   Abstract »    Full Text »    PDF »
Inhibition of Trail Gene Expression by Cyclopentenonic Prostaglandin 15-Deoxy-{Delta}12,14-Prostaglandin J2 in T Lymphocytes.
C. Fionda, F. Nappi, M. Piccoli, L. Frati, A. Santoni, and M. Cippitelli (2007)
Mol. Pharmacol. 72, 1246-1257
   Abstract »    Full Text »    PDF »
Combination Treatment with TRA-8 Anti Death Receptor 5 Antibody and CPT-11 Induces Tumor Regression in an Orthotopic Model of Pancreatic Cancer.
L. C. DeRosier, D. J. Buchsbaum, P. G. Oliver, Z.-Q. Huang, J. C. Sellers, W. E. Grizzle, W. Wang, T. Zhou, K. R. Zinn, J. W. Long, et al. (2007)
Clin. Cancer Res. 13, 5535s-5543s
   Abstract »    Full Text »    PDF »
Silibinin Sensitizes Human Glioma Cells to TRAIL-Mediated Apoptosis via DR5 Up-regulation and Down-regulation of c-FLIP and Survivin.
Y.-g. Son, E. H. Kim, J. Y. Kim, S. U. Kim, T. K. Kwon, A-R. Yoon, C.-O. Yun, and K. S. Choi (2007)
Cancer Res. 67, 8274-8284
   Abstract »    Full Text »    PDF »
Overexpression of FLIPL Is an Independent Marker of Poor Prognosis in Colorectal Cancer Patients.
G. J. Ullenhag, A. Mukherjee, N. F.S. Watson, A. H. Al-Attar, J. H. Scholefield, and L. G. Durrant (2007)
Clin. Cancer Res. 13, 5070-5075
   Abstract »    Full Text »    PDF »
Halocynthiaxanthin and Peridinin Sensitize Colon Cancer Cell Lines to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand.
T. Yoshida, T. Maoka, S. K. Das, K. Kanazawa, M. Horinaka, M. Wakada, Y. Satomi, H. Nishino, and T. Sakai (2007)
Mol. Cancer Res. 5, 615-625
   Abstract »    Full Text »    PDF »
CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme.
R. Martinez, F. Setien, C. Voelter, S. Casado, M. P. Quesada, G. Schackert, and M. Esteller (2007)
Carcinogenesis 28, 1264-1268
   Abstract »    Full Text »    PDF »
Interferon-{gamma} Sensitizes Resistant Ewing's Sarcoma Cells to Tumor Necrosis Factor Apoptosis-Inducing Ligand-Induced Apoptosis by Up-Regulation of Caspase-8 Without Altering Chemosensitivity.
A. Lissat, T. Vraetz, M. Tsokos, R. Klein, M. Braun, N. Koutelia, P. Fisch, M. E. Romero, L. Long, P. Noellke, et al. (2007)
Am. J. Pathol. 170, 1917-1930
   Abstract »    Full Text »    PDF »
Carcinoembryonic Antigen Inhibits Anoikis in Colorectal Carcinoma Cells by Interfering with Trail-R2 (DR5) Signaling.
R. N. Samara, L. M. Laguinge, and J. M. Jessup (2007)
Cancer Res. 67, 4774-4782
   Abstract »    Full Text »    PDF »
Concurrent gene therapy strategies effectively destroy synoviocytes of patients with rheumatoid arthritis.
E. Terzioglu, A. Bisgin, A. D. Sanlioglu, M. Ulker, V. Yazisiz, S. Tuzuner, and S. Sanlioglu (2007)
Rheumatology 46, 783-789
   Abstract »    Full Text »    PDF »
Cytosolic Activation of Cathepsins Mediates Parvovirus H-1-Induced Killing of Cisplatin and TRAIL-Resistant Glioma Cells.
M. Di Piazza, C. Mader, K. Geletneky, M. Herrero y Calle, E. Weber, J. Schlehofer, L. Deleu, and J. Rommelaere (2007)
J. Virol. 81, 4186-4198
   Abstract »    Full Text »    PDF »
Targeting TRAIL Agonistic Receptors for Cancer Therapy.
C. Carlo-Stella, C. Lavazza, A. Locatelli, L. Vigano, A. M. Gianni, and L. Gianni (2007)
Clin. Cancer Res. 13, 2313-2317
   Abstract »    Full Text »    PDF »
High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts.
H. Kim, T. R. Chaudhuri, D. J. Buchsbaum, D. Wang, and K. R. Zinn (2007)
Mol. Cancer Ther. 6, 866-875
   Abstract »    Full Text »    PDF »
Evidence that Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Induction by 5-Aza-2'-Deoxycytidine Sensitizes Human Breast Cancer Cells to Adriamycin.
J. Xu, J.-Y. Zhou, M. A. Tainsky, and G. S. Wu (2007)
Cancer Res. 67, 1203-1211
   Abstract »    Full Text »    PDF »
Hepatitis B Virus Sensitizes Hepatocytes to TRAIL-Induced Apoptosis through Bax.
X. Liang, Y. Liu, Q. Zhang, L. Gao, L. Han, C. Ma, L. Zhang, Y. H. Chen, and W. Sun (2007)
J. Immunol. 178, 503-510
   Abstract »    Full Text »    PDF »
Cationic Albumin-Conjugated Pegylated Nanoparticles Allow Gene Delivery into Brain Tumors via Intravenous Administration.
W. Lu, Q. Sun, J. Wan, Z. She, and X.-G. Jiang (2006)
Cancer Res. 66, 11878-11887
   Abstract »    Full Text »    PDF »
Blockade of transforming growth factor-{beta}-activated kinase 1 activity enhances TRAIL-induced apoptosis through activation of a caspase cascade.
M.-K. Choo, N. Kawasaki, P. Singhirunnusorn, K. Koizumi, S. Sato, S. Akira, I. Saiki, and H. Sakurai (2006)
Mol. Cancer Ther. 5, 2970-2976
   Abstract »    Full Text »    PDF »
Mithramycin A sensitizes cancer cells to TRAIL-mediated apoptosis by down-regulation of XIAP gene promoter through Sp1 sites..
T.-J. Lee, E. M. Jung, J. T. Lee, S. Kim, J.-W. Park, K. S. Choi, and T. K. Kwon (2006)
Mol. Cancer Ther. 5, 2737-2746
   Abstract »    Full Text »    PDF »
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Is Required for Tumor Necrosis Factor {alpha}-Mediated Sensitization of Human Breast Cancer Cells to Chemotherapy..
J. Xu, J.-Y. Zhou, and G. S. Wu (2006)
Cancer Res. 66, 10092-10099
   Abstract »    Full Text »    PDF »
Systemic Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Delivery Shows Antiatherosclerotic Activity in Apolipoprotein E-Null Diabetic Mice.
P. Secchiero, R. Candido, F. Corallini, S. Zacchigna, B. Toffoli, E. Rimondi, B. Fabris, M. Giacca, and G. Zauli (2006)
Circulation 114, 1522-1530
   Abstract »    Full Text »    PDF »
Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2..
D. Merino, N. Lalaoui, A. Morizot, P. Schneider, E. Solary, and O. Micheau (2006)
Mol. Cell. Biol. 26, 7046-7055
   Abstract »    Full Text »    PDF »
Constitutively Activated Nuclear Factor-{kappa}B, but not Induced NF-{kappa}B, Leads to TRAIL Resistance by Up-Regulation of X-Linked Inhibitor of Apoptosis Protein in Human Cancer Cells.
S. J. Braeuer, C. Buneker, A. Mohr, and R. M. Zwacka (2006)
Mol. Cancer Res. 4, 715-728
   Abstract »    Full Text »    PDF »
Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through CHOP-independent DR5 upregulation.
E. M. Jung, J.-W. Park, K. S. Choi, J.-W. Park, H. I. Lee, K.-S. Lee, and T. K. Kwon (2006)
Carcinogenesis 27, 2008-2017
   Abstract »    Full Text »    PDF »
Inducible Resistance of Tumor Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 2-Mediated Apoptosis by Generation of a Blockade at the Death Domain Function..
Y. Li, H. Wang, Z. Wang, S. Makhija, D. Buchsbaum, A. LoBuglio, R. Kimberly, and T. Zhou (2006)
Cancer Res. 66, 8520-8528
   Abstract »    Full Text »    PDF »
Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells.
T.-a. Matsui, Y. Sowa, T. Yoshida, H. Murata, M. Horinaka, M. Wakada, R. Nakanishi, T. Sakabe, T. Kubo, and T. Sakai (2006)
Carcinogenesis 27, 1768-1777
   Abstract »    Full Text »    PDF »
Nitrosylcobalamin Promotes Cell Death via S Nitrosylation of Apo2L/TRAIL Receptor DR4.
Z. Tang, J. A. Bauer, B. Morrison, and D. J. Lindner (2006)
Mol. Cell. Biol. 26, 5588-5594
   Abstract »    Full Text »    PDF »
Therapeutic advantage of combining calcium channel blockers and TRAIL in prostate cancer..
I. Kaddour-Djebbar, V. Lakshmikanthan, R. B. Shirley, Y. Ma, R. W. Lewis, and M. V. Kumar (2006)
Mol. Cancer Ther. 5, 1958-1966
   Abstract »    Full Text »    PDF »
Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity..
A. Lundqvist, S. I. Abrams, D. S. Schrump, G. Alvarez, D. Suffredini, M. Berg, and R. Childs (2006)
Cancer Res. 66, 7317-7325
   Abstract »    Full Text »    PDF »
Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL..
J. Cheng, B. L. Hylander, M. R. Baer, X. Chen, and E. A. Repasky (2006)
Mol. Cancer Ther. 5, 1844-1853
   Abstract »    Full Text »    PDF »
Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model..
L. M. Thai, A. Labrinidis, S. Hay, V. Liapis, S. Bouralexis, K. Welldon, B. J. Coventry, D. M. Findlay, and A. Evdokiou (2006)
Cancer Res. 66, 5363-5370
   Abstract »    Full Text »    PDF »
The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor-related apoptosis-inducing ligand..
M. Horinaka, T. Yoshida, T. Shiraishi, S. Nakata, M. Wakada, and T. Sakai (2006)
Mol. Cancer Ther. 5, 945-951
   Abstract »    Full Text »    PDF »
Evolution of Broad Host Range in Retroviruses Leads to Cell Death Mediated by Highly Cytopathic Variants.
G. J. A. Rainey and J. M. Coffin (2006)
J. Virol. 80, 562-570
   Abstract »    Full Text »    PDF »
Histone Deacetylase Inhibitors Modulate the Sensitivity of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Resistant Bladder Tumor Cells.
J. K. Earel Jr., R. L. VanOosten, and T. S. Griffith (2006)
Cancer Res. 66, 499-507
   Abstract »    Full Text »    PDF »
Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Activating Agents.
E. K. Rowinsky (2005)
J. Clin. Oncol. 23, 9394-9407
   Abstract »    Full Text »    PDF »
Pretreatment of Acetylsalicylic Acid Promotes Tumor Necrosis Factor-related Apoptosis-inducing Ligand-induced Apoptosis by Down-regulating BCL-2 Gene Expression.
K. M. Kim, J. J. Song, J. Y. An, Y. T. Kwon, and Y. J. Lee (2005)
J. Biol. Chem. 280, 41047-41056
   Abstract »    Full Text »    PDF »
Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP.
L. Galligan, D. B. Longley, M. McEwan, T. R. Wilson, K. McLaughlin, and P. G. Johnston (2005)
Mol. Cancer Ther. 4, 2026-2036
   Abstract »    Full Text »    PDF »
Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5).
E. M. Jung, J. H. Lim, T. J. Lee, J.-W. Park, K. S. Choi, and T. K. Kwon (2005)
Carcinogenesis 26, 1905-1913
   Abstract »    Full Text »    PDF »
Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes.
F. Rubio-Moscardo, D. Blesa, C. Mestre, R. Siebert, T. Balasas, A. Benito, A. Rosenwald, J. Climent, J. I. Martinez, M. Schilhabel, et al. (2005)
Blood 106, 3214-3222
   Abstract »    Full Text »    PDF »
Identification of MMP-15 as an Anti-apoptotic Factor in Cancer Cells.
R. Abraham, J. Schafer, M. Rothe, J. Bange, P. Knyazev, and A. Ullrich (2005)
J. Biol. Chem. 280, 34123-34132
   Abstract »    Full Text »    PDF »
Protein Kinase C-{varepsilon} Regulates the Apoptosis and Survival of Glioma Cells.
H. Okhrimenko, W. Lu, C. Xiang, N. Hamburger, G. Kazimirsky, and C. Brodie (2005)
Cancer Res. 65, 7301-7309
   Abstract »    Full Text »    PDF »
Tunicamycin Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Human Prostate Cancer Cells.
T. Shiraishi, T. Yoshida, S. Nakata, M. Horinaka, M. Wakada, Y. Mizutani, T. Miki, and T. Sakai (2005)
Cancer Res. 65, 6364-6370
   Abstract »    Full Text »    PDF »
Proteasome Inhibitor MG132 Induces Death Receptor 5 through CCAAT/Enhancer-Binding Protein Homologous Protein.
T. Yoshida, T. Shiraishi, S. Nakata, M. Horinaka, M. Wakada, Y. Mizutani, T. Miki, and T. Sakai (2005)
Cancer Res. 65, 5662-5667
   Abstract »    Full Text »    PDF »
Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Immune Response to Influenza Virus Infection in Mice.
E. Ishikawa, M. Nakazawa, M. Yoshinari, and M. Minami (2005)
J. Virol. 79, 7658-7663
   Abstract »    Full Text »    PDF »
Synthetic Triterpenoids Cooperate with Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand to Induce Apoptosis of Breast Cancer Cells.
M. L. Hyer, R. Croxton, M. Krajewska, S. Krajewski, C. L. Kress, M. Lu, N. Suh, M. B. Sporn, V. L. Cryns, J. M. Zapata, et al. (2005)
Cancer Res. 65, 4799-4808
   Abstract »    Full Text »    PDF »
Bortezomib Abolishes Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance via a p21-Dependent Mechanism in Human Bladder and Prostate Cancer Cells.
L. M. Lashinger, K. Zhu, S. A. Williams, M. Shrader, C. P.N. Dinney, and D. J. McConkey (2005)
Cancer Res. 65, 4902-4908
   Abstract »    Full Text »    PDF »
Contribution of Epigenetic Silencing of Tumor Necrosis Factor-Related Apoptosis Inducing Ligand Receptor 1 (DR4) to TRAIL Resistance and Ovarian Cancer.
P. Horak, D. Pils, G. Haller, I. Pribill, M. Roessler, S. Tomek, R. Horvat, R. Zeillinger, C. Zielinski, and M. Krainer (2005)
Mol. Cancer Res. 3, 335-343
   Abstract »    Full Text »    PDF »
Resistance and Susceptibility of Human Uveal Melanoma Cells to TRAIL-Induced Apoptosis.
H. Li, J. Y. Niederkorn, S. Neelam, and H. Alizadeh (2005)
Arch Ophthalmol 123, 654-661
   Abstract »    Full Text »    PDF »
A Study of TRAIL Receptors in Squamous Cell Carcinoma of the Head and Neck.
M. S. Teng, M. S. Brandwein-Gensler, M. S. Teixeira, J. A. Martignetti, and D. C. Duffey (2005)
Arch Otolaryngol Head Neck Surg 131, 407-412
   Abstract »    Full Text »    PDF »
Target Cell-Restricted Apoptosis Induction of Acute Leukemic T Cells by a Recombinant Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Fusion Protein with Specificity for Human CD7.
E. Bremer, D. F. Samplonius, M. Peipp, L. van Genne, B.-J. Kroesen, G. H. Fey, M. Gramatzki, L. F.M.H. de Leij, and W. Helfrich (2005)
Cancer Res. 65, 3380-3388
   Abstract »    Full Text »    PDF »
Enhanced Apoptosis and Tumor Regression Induced by a Direct Agonist Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 2.
K. Motoki, E. Mori, A. Matsumoto, M. Thomas, T. Tomura, R. Humphreys, V. Albert, M. Muto, H. Yoshida, M. Aoki, et al. (2005)
Clin. Cancer Res. 11, 3126-3135
   Abstract »    Full Text »    PDF »
Caspase-10 Sensitizes Breast Carcinoma Cells to TRAIL-Induced but Not Tumor Necrosis Factor-Induced Apoptosis in a Caspase- 3-Dependent Manner.
I. H. Engels, G. Totzke, U. Fischer, K. Schulze-Osthoff, and R. U. Janicke (2005)
Mol. Cell. Biol. 25, 2808-2818
   Abstract »    Full Text »    PDF »
Dengue virus-induced apoptosis in hepatic cells is partly mediated by Apo2 ligand/tumour necrosis factor-related apoptosis-inducing ligand.
T. Matsuda, A. Almasan, M. Tomita, K. Tamaki, M. Saito, M. Tadano, H. Yagita, T. Ohta, and N. Mori (2005)
J. Gen. Virol. 86, 1055-1065
   Abstract »    Full Text »    PDF »
E1A Sensitizes Cancer Cells to TRAIL-Induced Apoptosis through Enhancement of Caspase Activation.
R. Shao, D.-F. Lee, Y. Wen, Y. Ding, W. Xia, B. Ping, H. Yagita, B. Spohn, and M.-C. Hung (2005)
Mol. Cancer Res. 3, 219-226
   Abstract »    Full Text »    PDF »
The Small Heat Shock Protein {alpha}B-crystallin Is a Novel Inhibitor of TRAIL-induced Apoptosis That Suppresses the Activation of Caspase-3.
M. C. Kamradt, M. Lu, M. E. Werner, T. Kwan, F. Chen, A. Strohecker, S. Oshita, J. C. Wilkinson, C. Yu, P. G. Oliver, et al. (2005)
J. Biol. Chem. 280, 11059-11066
   Abstract »    Full Text »    PDF »
Simultaneous Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling and Enhanced Activation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor-mediated Apoptosis Induction by an scFv:sTRAIL Fusion Protein with Specificity for Human EGFR.
E. Bremer, D. F. Samplonius, L. van Genne, M. H. Dijkstra, B. J. Kroesen, L. F. M. H. de Leij, and W. Helfrich (2005)
J. Biol. Chem. 280, 10025-10033
   Abstract »    Full Text »    PDF »
Predominant Bcl-XL Knockdown Disables Antiapoptotic Mechanisms: Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Based Triple Chemotherapy Overcomes Chemoresistance in Pancreatic Cancer Cells In vitro.
J. Bai, J. Sui, A. Demirjian, C. M. Vollmer Jr., W. Marasco, and M. P. Callery (2005)
Cancer Res. 65, 2344-2352
   Abstract »    Full Text »    PDF »
Linking of N-Myc to Death Receptor Machinery in Neuroblastoma Cells.
H. Cui, T. Li, and H.-F. Ding (2005)
J. Biol. Chem. 280, 9474-9481
   Abstract »    Full Text »    PDF »
DR5 Knockout Mice Are Compromised in Radiation-Induced Apoptosis.
N. Finnberg, J. J. Gruber, P. Fei, D. Rudolph, A. Bric, S.-H. Kim, T. F. Burns, H. Ajuha, R. Page, G. S. Wu, et al. (2005)
Mol. Cell. Biol. 25, 2000-2013
   Abstract »    Full Text »    PDF »
Potent Anti-R5 Human Immunodeficiency Virus Type 1 Effects of a CCR5 Antagonist, AK602/ONO4128/GW873140, in a Novel Human Peripheral Blood Mononuclear Cell Nonobese Diabetic-SCID, Interleukin-2 Receptor {gamma}-Chain-Knocked-Out AIDS Mouse Model.
H. Nakata, K. Maeda, T. Miyakawa, S. Shibayama, M. Matsuo, Y. Takaoka, M. Ito, Y. Koyanagi, and H. Mitsuya (2005)
J. Virol. 79, 2087-2096
   Abstract »    Full Text »    PDF »
Resistance to Apo2 Ligand (Apo2L)/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)-Mediated Apoptosis and Constitutive Expression of Apo2L/TRAIL in Human T-Cell Leukemia Virus Type 1-Infected T-Cell Lines.
T. Matsuda, A. Almasan, M. Tomita, J.-n. Uchihara, M. Masuda, K. Ohshiro, N. Takasu, H. Yagita, T. Ohta, and N. Mori (2005)
J. Virol. 79, 1367-1378
   Abstract »    Full Text »    PDF »
Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling.
R. F. Kelley, K. Totpal, S. H. Lindstrom, M. Mathieu, K. Billeci, L. DeForge, R. Pai, S. G. Hymowitz, and A. Ashkenazi (2005)
J. Biol. Chem. 280, 2205-2212
   Abstract »    Full Text »    PDF »
Fas-associated Protein with Death Domain (FADD)-independent Recruitment of c-FLIPL to Death Receptor 5.
T.-G. Jin, A. Kurakin, N. Benhaga, K. Abe, M. Mohseni, F. Sandra, K. Song, B. K. Kay, and R. Khosravi-Far (2004)
J. Biol. Chem. 279, 55594-55601
   Abstract »    Full Text »    PDF »
Hypermethylation of the Death-Associated Protein Kinase Promoter Attenuates the Sensitivity to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Human Non-Small Cell Lung Cancer Cells.
X. Tang, W. Wu, S.-y. Sun, I. I. Wistuba, W. K. Hong, and L. Mao (2004)
Mol. Cancer Res. 2, 685-691
   Abstract »    Full Text »    PDF »
Partial Contribution of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)/TRAIL Receptor Pathway to Antitumor Effects of Interferon-{alpha}/5-Fluorouracil against Hepatocellular Carcinoma.
T. Yamamoto, H. Nagano, M. Sakon, H. Wada, H. Eguchi, M. Kondo, B. Damdinsuren, H. Ota, M. Nakamura, H. Wada, et al. (2004)
Clin. Cancer Res. 10, 7884-7895
   Abstract »    Full Text »    PDF »
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction.
S. Colucci, G. Brunetti, R. Rizzi, A. Zonno, G. Mori, G. Colaianni, D. Del Prete, R. Faccio, A. Liso, S. Capalbo, et al. (2004)
Blood 104, 3722-3730
   Abstract »    Full Text »    PDF »
Reduced Apoptosis and Ameliorated Listeriosis in TRAIL-Null Mice.
S.-J. Zheng, J. Jiang, H. Shen, and Y. H. Chen (2004)
J. Immunol. 173, 5652-5658
   Abstract »    Full Text »    PDF »
Persistent c-FLIP(L) Expression Is Necessary and Sufficient to Maintain Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated Apoptosis in Prostate Cancer.
X. Zhang, T.-G. Jin, H. Yang, W. C. DeWolf, R. Khosravi-Far, and A. F. Olumi (2004)
Cancer Res. 64, 7086-7091
   Abstract »    Full Text »    PDF »
Sodium butyrate sensitizes TRAIL-mediated apoptosis by induction of transcription from the DR5 gene promoter through Sp1 sites in colon cancer cells.
Y.-H. Kim, J.-W. Park, J.-Y. Lee, and T. K. Kwon (2004)
Carcinogenesis 25, 1813-1820
   Abstract »    Full Text »    PDF »
Non-steroidal anti-inflammatory drug activated gene (NAG-1) expression is closely related to death receptor-4 and -5 induction, which may explain sulindac sulfide induced gastric cancer cell apoptosis.
T. J. Jang, H. J. Kang, J. R. Kim, and C. H. Yang (2004)
Carcinogenesis 25, 1853-1858
   Abstract »    Full Text »    PDF »
Death Induction by Recombinant Native TRAIL and Its Prevention by a Caspase 9 Inhibitor in Primary Human Esophageal Epithelial Cells.
S.-H. Kim, K. Kim, J. G. Kwagh, D. T. Dicker, M. Herlyn, A. K. Rustgi, Y. Chen, and W. S. El-Deiry (2004)
J. Biol. Chem. 279, 40044-40052
   Abstract »    Full Text »    PDF »
TRAIL and KILLER Are Expressed and Induce Apoptosis in the Murine Preimplantation Embryo.
J. K. Riley, J. M. Heeley, A. H. Wyman, E. L. Schlichting, and K. H. Moley (2004)
Biol Reprod 71, 871-877
   Abstract »    Full Text »    PDF »
Deficient Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-induced Apoptosis.
Z. Jin, E. R. McDonald III, D. T. Dicker, and W. S. El-Deiry (2004)
J. Biol. Chem. 279, 35829-35839
   Abstract »    Full Text »    PDF »
Apo2 Ligand/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival.
H. Jin, R. Yang, S. Fong, K. Totpal, D. Lawrence, Z. Zheng, J. Ross, H. Koeppen, R. Schwall, and A. Ashkenazi (2004)
Cancer Res. 64, 4900-4905
   Abstract »    Full Text »    PDF »
TNF-related apoptosis-inducing ligand is involved in neutropenia of systemic lupus erythematosus.
W. Matsuyama, M. Yamamoto, I. Higashimoto, K.-i. Oonakahara, M. Watanabe, K. Machida, T. Yoshimura, N. Eiraku, M. Kawabata, M. Osame, et al. (2004)
Blood 104, 184-191
   Abstract »    Full Text »    PDF »
Inflammatory Cytokines and Postmyocardial Infarction Remodeling.
M. Nian, P. Lee, N. Khaper, and P. Liu (2004)
Circ. Res. 94, 1543-1553
   Abstract »    Full Text »    PDF »
Tissue Distribution of the Death Ligand TRAIL and Its Receptors.
D. C. Spierings, E. G. de Vries, E. Vellenga, F. A. van den Heuvel, J. J. Koornstra, J. Wesseling, H. Hollema, and S. de Jong (2004)
J. Histochem. Cytochem. 52, 821-831
   Abstract »    Full Text »    PDF »
The Role of Osteoprotegerin and Tumor Necrosis Factor-related Apoptosis-inducing Ligand in Human Microvascular Endothelial Cell Survival.
L. B. Pritzker, M. Scatena, and C. M. Giachelli (2004)
Mol. Biol. Cell 15, 2834-2841
   Abstract »    Full Text »    PDF »
Mcl-1 Mediates Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Human Cholangiocarcinoma Cells.
M. Taniai, A. Grambihler, H. Higuchi, N. Werneburg, S. F. Bronk, D. J. Farrugia, S. H. Kaufmann, and G. J. Gores (2004)
Cancer Res. 64, 3517-3524
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)